Dr. Mohler’s responsibility is to provide overall management and direction of the Bioanalytics, Metabolomics and Pharmacokinetics Shared Resource (BMPK) through two Associate Directors. Dr. Mohler has been engaged in translational research for 30 years. His research has focused upon the role for the androgen receptor (AR) in prostate cancer (CaP) recurrence after androgen deprivation therapy (ADT) and racial differences in CaP aggressiveness. These research activities have been supported primarily by a Program Project that ended 03/31/2017 after 17 years, “Prostate Cancer: Transition to Androgen-Independence” and the DOD Prostate Cancer Research Program funded “North Carolina-Louisiana Prostate Cancer Project (PCaP),” the largest population-based CaP study ever conducted (2,258 men with newly diagnosed CaP; involved 11 institutions). PCaP sought to compartmentalize the reasons for increased CaP mortality in African Americans. Thus far, racial differences in interaction between African-American CaP patients and the American Healthcare System seem to outweigh the impact of racial differences in CaP biology and host environment (diet) and genetics. PCaP has produced a total of 36 manuscripts thus far and 15 grants have been awarded to continue the interrogation of its data and biorepository.
Dr. Goey completed his PhD on clinical pharmacokinetic (PK) herb-drug interactions in oncology at Utrecht University and the Netherlands Cancer Institute. Subsequently, he completed a 3-year postdoctoral fellowship at the NCI Clinical Pharmacology Program in Bethesda MD. He conducted research spanning the entire drug development pipeline from drug discovery via target identification/validation to preclinical development and ultimately to clinical evaluation. Dr. Goey also conducted pharmacogenetic analyses on the HDAC inhibitor belinostat. During his second 3-year postdoctoral fellowship at the Personal Medicine Group at Erasmus Medical Center in Rotterdam (the Netherlands), he specialized in the field of pharmacogenetics in oncology. Dr. Goey’s independent research program focuses on pharmacogenetic research for personalized dosing of oncology agents to maximize tumor response while minimizing drug side effects. As Associate Director of PK/PD Modeling within the BMPK Shared Resource, Dr. Goey is responsible for projects that require PK/PD modeling, population PK/PD analysis, and simulations.
Joshua Prey has worked at Roswell Park since 2002 and has been with the BMPK Shared Resource (formerly PK/PD) since its inception in 2005. Joshua holds an MS degree in biology from SUNY Fredonia. As Research Project Administrator of Bioanalytics, Metabolomics & Pharmacokinetics for the resource, Joshua is responsible for day-to-day operations including project development, consultation, and budgeting. In addition, Joshua is involved in the development of new LC/MS/MS assays, sample analysis, and data interpretation.
Mass Spectrometry Scientist
Phone: 716-845-1300 x6822
Laboratory Operations Coordinator
Phone: 716-845-1300 x2829
Laboratory Technician/Quality Assurance
Phone: 716-845-1300 x6544